Heska Corporation (HSKA) Income Statement Analysis

See more : Element 25 Limited (ELMTF) Income Statement Analysis – Financial Results

Complete financial analysis of Heska Corporation (HSKA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Heska Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.

You may be interested

Heska Corporation (HSKA)

Industry: Medical - Devices

Sector: Healthcare

Website: https://www.heska.com

About Heska Corporation

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was founded in 1988 and is based in Loveland, Colorado.

Metric	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996
Revenue	257.31M	253.74M	197.32M	122.66M	127.45M	129.34M	130.08M	104.60M	89.84M	78.34M	72.81M	70.07M	65.45M	75.68M	81.65M	82.34M	75.06M	69.44M	67.69M	65.33M	51.33M	48.28M	52.68M	51.20M	39.80M	20.90M	10.00M
Cost of Revenue	146.14M	147.95M	116.03M	68.21M	70.81M	71.08M	76.19M	60.38M	54.12M	47.71M	41.70M	40.88M	40.66M	47.22M	52.81M	49.15M	44.41M	43.61M	42.25M	38.40M	30.20M	28.66M	29.23M	32.50M	25.50M	12.00M	5.40M
Gross Profit	111.17M	105.79M	81.29M	54.45M	56.64M	58.26M	53.89M	44.21M	35.72M	30.63M	31.10M	29.19M	24.79M	28.46M	28.84M	33.19M	30.65M	25.83M	25.44M	26.93M	21.13M	19.63M	23.44M	18.70M	14.30M	8.90M	4.60M
Gross Profit Ratio	43.20%	41.69%	41.20%	44.39%	44.44%	45.04%	41.43%	42.27%	39.76%	39.10%	42.72%	41.66%	37.88%	37.61%	35.33%	40.31%	40.83%	37.19%	37.58%	41.22%	41.16%	40.65%	44.50%	36.52%	35.93%	42.58%	46.00%
Research & Development	19.75M	6.98M	8.77M	8.24M	3.33M	2.00M	2.15M	1.66M	1.41M	1.50M	958.00K	1.65M	1.60M	1.72M	1.95M	2.68M	3.48M	3.75M	6.62M	6.77M	8.57M	13.57M	14.93M	17.00M	25.10M	22.40M	14.00M
General & Administrative	64.05M	54.52M	42.24M	18.20M	24.85M	14.81M	13.12M	12.66M	12.23M	11.13M	9.65M	9.12M	8.11M	8.17M	8.92M	8.93M	9.89M	7.19M	7.44M	7.08M	6.69M	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	47.66M	45.28M	38.47M	27.68M	24.66M	23.23M	22.09M	21.34M	19.16M	19.43M	18.34M	15.17M	14.73M	14.52M	17.64M	16.11M	14.36M	14.02M	15.62M	15.75M	13.13M	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	111.71M	99.81M	80.71M	45.88M	49.51M	38.04M	35.21M	34.00M	31.39M	30.56M	27.99M	24.29M	22.84M	22.70M	26.56M	25.03M	24.24M	21.21M	23.06M	22.83M	19.82M	21.86M	24.25M	26.30M	25.10M	19.60M	7.00M
Other Expenses	-923.00K	-44.00K	166.00K	-482.00K	62.00K	228.00K	7.00K	-102.00K	55.00K	-16.00K	-113.00K	1.02M	0.00	0.00	1.65M	1.10M	83.00K	1.86M	4.49M	5.91M	8.41M	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	131.47M	106.79M	89.48M	54.12M	52.84M	40.04M	37.36M	35.66M	32.80M	32.06M	28.94M	25.94M	24.43M	24.42M	28.74M	27.67M	27.57M	24.96M	29.68M	29.61M	28.45M	35.73M	44.14M	49.40M	56.50M	46.70M	23.30M
Cost & Expenses	277.61M	254.73M	205.52M	122.33M	123.65M	111.12M	113.55M	96.04M	86.93M	79.77M	70.65M	66.82M	65.09M	71.63M	81.55M	76.81M	71.99M	68.57M	71.93M	68.00M	58.65M	64.38M	73.38M	81.90M	82.00M	58.70M	28.70M
Interest Income	3.58M	1.80M	607.00K	661.00K	261.00K	167.00K	124.00K	172.00K	190.00K	127.00K	95.00K	268.00K	58.00K	64.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	1.54M	4.20M	6.37M	3.09M	310.00K	245.00K	160.00K	200.00K	206.00K	74.00K	117.00K	124.00K	189.00K	407.00K	640.00K	588.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	13.97M	13.56M	11.39M	4.92M	4.60M	4.75M	4.65M	4.19M	3.71M	2.50M	1.70M	2.05M	2.30M	2.57M	3.27M	2.18M	2.01M	2.01M	1.73M	1.89M	2.64M	3.72M	4.97M	6.10M	6.30M	4.70M	2.30M
EBITDA	-20.30M	-993.00K	-8.19M	327.00K	3.79M	18.22M	16.53M	8.56M	2.91M	-1.43M	2.16M	5.57M	2.71M	6.67M	4.47M	5.52M	4.79M	2.63M	-4.24M	-444.00K	-8.34M	-10.05M	-14.73M	-19.80M	-35.90M	-34.80M	-17.60M
EBITDA Ratio	-7.89%	-0.39%	-4.15%	0.27%	2.98%	14.09%	12.71%	8.18%	3.24%	-1.83%	2.96%	7.95%	4.15%	8.82%	5.47%	9.24%	6.38%	3.79%	-3.84%	-0.68%	-7.17%	-20.81%	-27.97%	-38.67%	-90.20%	-166.51%	-176.00%
Operating Income	-20.30M	-993.00K	-8.19M	-4.59M	3.75M	18.22M	16.53M	8.56M	2.91M	-1.43M	2.16M	3.25M	358.00K	4.04M	-681.00K	5.52M	3.08M	871.00K	-4.24M	-3.19M	-8.34M	-18.12M	-20.70M	-30.70M	-42.20M	-37.80M	-18.70M
Operating Income Ratio	-7.89%	-0.39%	-4.15%	-3.74%	2.94%	14.09%	12.71%	8.18%	3.24%	-1.83%	2.96%	4.64%	0.55%	5.34%	-0.83%	6.71%	4.10%	1.25%	-6.26%	-4.89%	-16.24%	-37.53%	-39.30%	-59.96%	-106.03%	-180.86%	-187.00%
Total Other Income/Expenses	-1.54M	-2.45M	-5.60M	-2.91M	13.00K	150.00K	-29.00K	-130.00K	39.00K	37.00K	-135.00K	117.00K	-289.00K	-306.00K	-640.00K	-588.00K	-1.04M	-774.00K	-575.00K	-214.00K	-334.00K	-2.33M	-1.00M	-4.80M	0.00	1.70M	1.20M
Income Before Tax	-21.83M	-3.44M	-13.79M	-2.58M	3.81M	18.37M	16.50M	8.43M	2.95M	-1.39M	2.02M	3.37M	69.00K	3.74M	-1.32M	4.93M	2.03M	97.00K	-4.82M	-3.41M	-9.34M	-20.45M	-21.70M	-35.50M	0.00	-36.10M	-17.50M
Income Before Tax Ratio	-8.49%	-1.36%	-6.99%	-2.11%	2.99%	14.20%	12.69%	8.06%	3.28%	-1.78%	2.78%	4.80%	0.11%	4.94%	-1.62%	5.99%	2.71%	0.14%	-7.11%	-5.22%	-18.20%	-42.36%	-41.20%	-69.34%	0.00%	-172.73%	-175.00%
Income Tax Expense	-3.41M	-3.57M	239.00K	-1.45M	-2.12M	8.91M	4.34M	2.91M	1.35M	-454.00K	820.00K	1.22M	51.00K	1.50M	-471.00K	-29.88M	206.00K	-185.00K	575.00K	51.00K	1.34M	2.59M	1.17M	5.10M	2.10M	-500.00K	-700.00K
Net Income	-18.42M	132.00K	-14.03M	-1.14M	5.85M	9.95M	10.51M	5.24M	2.60M	-1.20M	1.20M	2.15M	18.00K	2.24M	-850.00K	34.81M	1.83M	282.00K	-4.82M	-3.46M	-8.67M	-18.69M	-21.87M	-35.80M	-44.30M	-37.30M	-18.00M
Net Income Ratio	-7.16%	0.05%	-7.11%	-0.93%	4.59%	7.70%	8.08%	5.01%	2.90%	-1.53%	1.65%	3.06%	0.03%	2.96%	-1.04%	42.28%	2.44%	0.41%	-7.11%	-5.30%	-16.89%	-38.71%	-41.52%	-69.92%	-111.31%	-178.47%	-180.00%
EPS	-1.78	0.01	-1.62	-0.15	0.74	1.42	1.55	0.80	0.44	-0.21	0.23	0.41	0.00	0.43	-0.16	6.80	0.40	0.10	-0.98	-0.72	-1.82	-4.80	-6.47	-13.12	-17.94	-23.20	-14.34
EPS Diluted	-1.78	0.01	-1.62	-0.15	0.74	1.30	1.43	0.74	0.41	-0.21	0.22	0.40	0.00	0.43	-0.16	6.30	0.30	0.10	-0.98	-0.72	-1.82	-4.80	-6.47	-13.12	-17.94	-23.20	-14.34
Weighted Avg Shares Out	10.34M	10.02M	8.65M	7.45M	7.86M	7.03M	6.78M	6.51M	5.95M	5.76M	5.33M	5.24M	5.22M	5.21M	5.17M	5.11M	5.03M	4.97M	4.90M	4.81M	4.77M	3.89M	3.38M	2.73M	2.47M	1.61M	1.25M
Weighted Avg Shares Out (Dil)	10.34M	10.02M	8.65M	7.45M	7.86M	7.64M	7.36M	7.07M	6.41M	5.76M	5.49M	5.34M	5.25M	5.21M	5.17M	5.55M	5.29M	5.04M	4.90M	4.81M	4.77M	3.89M	3.38M	2.73M	2.47M	1.61M	1.25M

Heska (HSKA) Tops Q4 Earnings and Revenue Estimates

February 28, 2022zacks.com

Heska (HSKA) delivered earnings and revenue surprises of 9.38% and 3.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Heska (HSKA)

February 24, 2022zacks.com

Heska (HSKA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Heska (HSKA) Expected to Beat Earnings Estimates: Should You Buy?

February 21, 2022zacks.com

Heska (HSKA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Heska Corp Brands, Inc. (HSKA) CEO Kevin Wilson on Q3 2021 Results - Earnings Call Transcript

November 6, 2021seekingalpha.com

Heska Corp Brands, Inc. (HSKA) CEO Kevin Wilson on Q3 2021 Results - Earnings Call Transcript

7 A-Rated Healthcare Stocks to Buy for the Long Haul

November 1, 2021investorplace.com

It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future. The post 7 A-Rated Healthcare Stocks to Buy for the Long Haul appeared...

Research opinion: Heska Corp is a ‘strong sell'

October 25, 2021invezz.com

Shares of Heska Corp (NASDAQ: HSKA) have lost nearly 20% since late August, but Spruce Point Capital Management says the stock could crash another 60% from here as its current premium valuation is “nonsensical”. Heska's Element AIM will disappoint In...

Spruce Point Capital Management Announces Investment Opinion: Releases Report and “Strong Sell” Research Opinion on Heska Corporation (Nasdaq: HSKA)

October 25, 2021businesswire.com

NEW YORK--(BUSINESS WIRE)--Spruce Point Capital Management, LLC (“Spruce Point” or “we” or “us”), a New York-based investment management firm that focuses on forensic research and short-selling, today issued a detailed report entitled “Scoop This Poop From Your Portfolio” that outlines...